Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Evolution of Treatment and Predictive Factors in SCCHN
share announcement

Evolution of Treatment and Predictive Factors in SCCHN

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (5 June 2023) | Viewed by 5498

Special Issue Editor

Prof. Dr. Denis Soulieres

E-Mail Website
Guest Editor
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM) and Institut du cancer de Montréal, Montréal, Québec, Canada
Interests: HNSCC; immunotherapy; biomarkers; mRCC; targeted therapy; DPYD
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancers will hold a Special Issue on squamous cell carcinoma of the head and neck (SCCHN). This Special Issue is dedicated to discussing current standard practices and future perspectives in treatment and predictive factors in SCCHN. The articles included herein cover a broad range of topics, with the goal being to provide a comprehensive overview of the state-of-the-art knowledge related to SCCHN.

In this Special Issue, “Evolution of treatment and predictive factors in SCCHN”, authors are invited to contribute cutting-edge studies that will further highlight the contents of immunotherapy, targeted therapy and prognostic markers in SCCHN.

I would be honored to have you collaborate for this Special Edition. Specifically, and knowing some of your work, I would like to discuss further initiatives that are not yet published and could be included in this journal. Evidently, any work will require revisions by the standards established by the journal.

I look forward to receiving your submissions.

Prof. Dr. Denis Soulieres
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SCCHN
  • biomarkers
  • immunotherapy
  • targeted therapy
  • prognostic markers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 748 KiB  
Article
Discovering the Clinical and Prognostic Role of Pan-Immune-Inflammation Values on Oral Cavity Squamous Cell Carcinoma
by Chia-Chi Yeh, Huang-Kai Kao, Yenlin Huang, Tsung-You Tsai, Chi-Kuang Young, Shao-Yu Hung, Chuieng-Yi Lu and Kai-Ping Chang
Cancers 2023, 15(1), 322; https://doi.org/10.3390/cancers15010322 - 3 Jan 2023
Cited by 17 | Viewed by 2725
Abstract
A newly introduced pan-immune-inflammation value (PIV) was not evaluated for its role in oral cavity squamous cell carcinoma (OSCC). In this study, the PIV was calculated with the following equation (neutrophil count × platelet count × monocyte count)/lymphocyte count from the results of [...] Read more.
A newly introduced pan-immune-inflammation value (PIV) was not evaluated for its role in oral cavity squamous cell carcinoma (OSCC). In this study, the PIV was calculated with the following equation (neutrophil count × platelet count × monocyte count)/lymphocyte count from the results of the automated hematology analyzers in 853 OSCC patients from 2005 to 2017. The optimal cutoff for the preoperative PIV was 268, as determined by a receiver operating characteristic curve. Significant differences were observed for alcohol consumption, smoking, pT status, pN status, overall pathological status, extranodal extension, cell differentiation, depth of invasion, and perineural invasion between higher and lower PIV patients (all p values < 0.05). Kaplan-Meier and univariate regression analyses indicated that higher PIV was associated with worse overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival (all p values < 0.001). Multivariate analyses adjusted by various factors further demonstrated that PIV was an independent prognostic factor for overall and distant metastasis-free survival (p = 0.027, HR: 1.281 and p = 0.031, HR: 1.274, respectively). In conclusion, a higher PIV level was associated with poor clinicopathological factors in OSCC patients and could be used to predict poor posttreatment outcomes, especially for overall and distant metastasis-free survival. Full article
(This article belongs to the Special Issue Evolution of Treatment and Predictive Factors in SCCHN)
►▼ Show Figures

Figure 1

16 pages, 1904 KiB  
Article
Loss of MMP-27 Predicts Mandibular Bone Invasion in Oral Squamous Cell Carcinoma
by Jonas Eichberger, Florian Weber, Gerrit Spanier, Michael Gerken, Stephan Schreml, Daniela Schulz, Mathias Fiedler, Nils Ludwig, Richard Josef Bauer, Torsten Eugen Reichert and Tobias Ettl
Cancers 2022, 14(16), 4044; https://doi.org/10.3390/cancers14164044 - 22 Aug 2022
Cited by 3 | Viewed by 2056
Abstract
Invasion of the mandibular bone is frequent in oral squamous cell carcinoma (OSCC), which often results in extensive ablative and reconstructive procedures for the patient. The purpose of this single-center, retrospective study was to identify and evaluate potential biomarkers and risk factors for [...] Read more.
Invasion of the mandibular bone is frequent in oral squamous cell carcinoma (OSCC), which often results in extensive ablative and reconstructive procedures for the patient. The purpose of this single-center, retrospective study was to identify and evaluate potential biomarkers and risk factors for bone invasion in OSCC. Initially, in silico gene expression analysis was performed for different HNSCC tumor T-stages to find factors associated with invasive (T4a) tumor growth. Afterwards, the protein expression of bone-metabolizing MMP-27, TNFRSF11B (Osteoprotegerin, OPG), and TNFSF11 (RANKL) was investigated via Tissue Microarrays (TMAs) for their impact on mandibular bone invasion. TMAs were assembled from the bone–tumor interface of primary OSCCs of the floor of the mouth and gingiva from 119 patients. Sixty-four carcinomas with patho-histological jaw invasion (pT4a) were compared to 55 carcinomas growing along the mandible without invasion (pT2, pT3). Tissue samples were additionally evaluated for patterns of invasion using the WPOI grading system. Statistical analysis of in silico data revealed decreased MMP-27 mRNA expression to be strongly associated with the pT4a-stage in OSCC, indicating invasive tumor growth with infiltration of adjacent anatomical structures. Our own clinico-pathological data on OSCCs presented a significant decrease of MMP-27 in tumors invading the nearby mandible (pT4a), compared to pT2 and pT3 tumors without bone invasion. Loss of MMP27 evolved as the strongest predictor of mandibular bone invasion in binary logistic regression analysis. To our knowledge, this is the first study investigating the role of MMP-27 expression in OSCC and demonstrating the importance of the loss of MMP-27 in mandibular bone invasion. Full article
(This article belongs to the Special Issue Evolution of Treatment and Predictive Factors in SCCHN)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop